Streptococcus pyogenes in tumor treatment: the past, present and future
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://hdl.handle.net/10216/128759 |
Resumo: | In light of the recent emergence of immunotherapy as a possible treatment in Oncology, and considering the concept of spontaneous tumor regression following an infectious episode, the present work aimed to understand the role of infectious diseases in tumor treatment, specifically concerning the pathogen Streptococcus pyogenes. The pertinence of this bacteria in cancer treatment has been investigated throughout the last century and has achieved promising results, but it still isn't a reliable tool. This work reviews the most relevant aspects of Streptococcus pyogenes usage in cancer treatment, including: Streptococcus pyogenes-based formulations, administration protocols used, possible mechanisms of action for the evidenced tumor regression, main side effects observed and possibilities for clinical assessment of responders and non-responders, as well as the most relevant differences in the outcomes observed in different clinical studies. The current evidence suggests that Streptococcus pyogenes has established itself as a reliable inducer of the immune system, which can positively contribute to cancer treatment. However, further clinical evaluations are still needed to validate the present findings and allow for a conclusion to be drawn. |
id |
RCAP_15f0ad2acc332a638571c80488ffca66 |
---|---|
oai_identifier_str |
oai:repositorio-aberto.up.pt:10216/128759 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Streptococcus pyogenes in tumor treatment: the past, present and futureMedicina clínicaClinical medicineIn light of the recent emergence of immunotherapy as a possible treatment in Oncology, and considering the concept of spontaneous tumor regression following an infectious episode, the present work aimed to understand the role of infectious diseases in tumor treatment, specifically concerning the pathogen Streptococcus pyogenes. The pertinence of this bacteria in cancer treatment has been investigated throughout the last century and has achieved promising results, but it still isn't a reliable tool. This work reviews the most relevant aspects of Streptococcus pyogenes usage in cancer treatment, including: Streptococcus pyogenes-based formulations, administration protocols used, possible mechanisms of action for the evidenced tumor regression, main side effects observed and possibilities for clinical assessment of responders and non-responders, as well as the most relevant differences in the outcomes observed in different clinical studies. The current evidence suggests that Streptococcus pyogenes has established itself as a reliable inducer of the immune system, which can positively contribute to cancer treatment. However, further clinical evaluations are still needed to validate the present findings and allow for a conclusion to be drawn.2020-06-092020-06-09T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://hdl.handle.net/10216/128759TID:202613950engJoana Oliveira e Sousa Ferraz Brandãoinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T15:33:06Zoai:repositorio-aberto.up.pt:10216/128759Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:26:23.905958Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Streptococcus pyogenes in tumor treatment: the past, present and future |
title |
Streptococcus pyogenes in tumor treatment: the past, present and future |
spellingShingle |
Streptococcus pyogenes in tumor treatment: the past, present and future Joana Oliveira e Sousa Ferraz Brandão Medicina clínica Clinical medicine |
title_short |
Streptococcus pyogenes in tumor treatment: the past, present and future |
title_full |
Streptococcus pyogenes in tumor treatment: the past, present and future |
title_fullStr |
Streptococcus pyogenes in tumor treatment: the past, present and future |
title_full_unstemmed |
Streptococcus pyogenes in tumor treatment: the past, present and future |
title_sort |
Streptococcus pyogenes in tumor treatment: the past, present and future |
author |
Joana Oliveira e Sousa Ferraz Brandão |
author_facet |
Joana Oliveira e Sousa Ferraz Brandão |
author_role |
author |
dc.contributor.author.fl_str_mv |
Joana Oliveira e Sousa Ferraz Brandão |
dc.subject.por.fl_str_mv |
Medicina clínica Clinical medicine |
topic |
Medicina clínica Clinical medicine |
description |
In light of the recent emergence of immunotherapy as a possible treatment in Oncology, and considering the concept of spontaneous tumor regression following an infectious episode, the present work aimed to understand the role of infectious diseases in tumor treatment, specifically concerning the pathogen Streptococcus pyogenes. The pertinence of this bacteria in cancer treatment has been investigated throughout the last century and has achieved promising results, but it still isn't a reliable tool. This work reviews the most relevant aspects of Streptococcus pyogenes usage in cancer treatment, including: Streptococcus pyogenes-based formulations, administration protocols used, possible mechanisms of action for the evidenced tumor regression, main side effects observed and possibilities for clinical assessment of responders and non-responders, as well as the most relevant differences in the outcomes observed in different clinical studies. The current evidence suggests that Streptococcus pyogenes has established itself as a reliable inducer of the immune system, which can positively contribute to cancer treatment. However, further clinical evaluations are still needed to validate the present findings and allow for a conclusion to be drawn. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06-09 2020-06-09T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://hdl.handle.net/10216/128759 TID:202613950 |
url |
https://hdl.handle.net/10216/128759 |
identifier_str_mv |
TID:202613950 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799136177289166848 |